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After two decades of genetic testing and research, the
BRCA1 and BRCA2 genes are two of the most
well-characterized genes in the human genome. As a
result, variants of uncertain significance (VUS; also called
variants of unknown significance) are reported less
frequently than for genes that have been less thoroughly
studied. However, VUS continue to be uncovered, even
for BRCA1/2. The increasing use of multi-gene panels and
whole-genome and whole-exome sequencing will lead
to higher rates of VUS detection because more genes
are being tested, and most genomic loci have been far
less intensively characterized than BRCA1/2. In this article,
we draw attention to ethical and policy-related issues that
will emerge. Experience garnered from BRCA1/2 testing is
a useful introduction to the challenges of detecting VUS
in other genetic testing contexts, while features unique to
BRCA1/2 suggest key differences between the BRCA
experience and the current challenges of multi-gene
panels in clinical care. We propose lines of research and
policy development, emphasizing the importance of
pooling data into a centralized open-access database for
the storage of gene variants to improve VUS interpretation.
In addition, establishing ethical norms and regulated
practices for sharing and curating data, analytical
algorithms, interpretive frameworks and patient
re-contact are important policy areas.The experience garnered from BRCA gene testing canBackground
There is an increasing move towards the use of multi-
gene panels, whole-genome sequencing (WGS) and
whole-exome sequencing (WES) in clinical care. In con-
trast to genetic testing for mutations in a single gene or in
a limited number of high-penetrance genes associated
with a particular disease (such as BRCA1/2), multi-gene* Correspondence: bob.cd@duke.edu
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unless otherwise stated.panels and WGS involve testing numerous variably pene-
trant genes or the entire genome. One consequence of
using panels or WGS/WES is that genetic testing results
are more likely to include variants of uncertain signifi-
cance (VUS). A key challenge is that the clinical signifi-
cance of a VUS result for disease risk is by definition
unclear. This makes clinical management recommenda-
tions more complex, while also potentially creating anxiety
or misunderstanding among patients. Further studies of
the variant in question may lead to a VUS result being re-
classified as either deleterious or not, raising policy and
ethical questions about the duty to re-contact patients and
who is ultimately responsible for this task. The methods of
VUS classification and reclassification vary and are the
subject of multiple international efforts, although there
remain no universally accepted standards or methods
for determining pathogenicity and reporting VUS re-
sults [1]. Collaborative efforts to collate data on VUS
are essential to improving the current difficulties cre-
ated by VUS results.
BRCA1/2 genetic testing, which has been in use for
nearly two decades, still produces VUS results regularly
[2]. Multi-gene panels and WGS/WES will inevitably in-
crease the number of VUS found because more genes
are included in the analyses [3,4]. In comparison with
BRCA1/2, there will be far less information regarding
new VUS results because far fewer genetic tests and
studies have been completed for other genes.
help inform how new developments in genomics will play
out, not only for BRCA genes, but for others as well. At
the same time, specific unique features of BRCA1/2 - such
as the longstanding patent held by Myriad Genetics in the
United States until recently, as well as the great length and
short exon sequences of these two genes - also suggest key
differences between the BRCA experience and the current
challenges of multi-gene panels and WGS in clinical care.
Interpreting the clinical meaning of newly discovered vari-
ants will be one of the major challenges of ‘genomic’, or
‘precision’, medicine.Ltd. The licensee has exclusive rights to distribute this article, in any medium, for
time, the article is available under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tory and data management difficulties that are presented
by VUS found during BRCA gene testing, and draw at-
tention to ethical, legal and policy-related issues that will
emerge as more testing is carried out on an increasing
number of genes. We then suggest key areas for research
and policy development, particularly the importance of a
centralized open-access database for the storage of gene
variants.Experiences from BRCA: VUS results and
challenges for clinical management
The BRCA1 and BRCA2 genes were initially sequenced
and characterized two decades ago, in 1994 and
1995, respectively [5-8]. They have since become two
of the most thoroughly studied genes in the human
genome. Deleterious mutation carriers have a signifi-
cantly increased lifetime risk of breast and ovarian
cancer, as well as other cancers [9]. Genetic testing
to determine whether an individual harbors a dele-
terious BRCA1/2 mutation plays an important role in
assessing risk and determining clinical management
[10,11].
However, even for well-studied genes like BRCA1/2,
new VUS continue to appear. A VUS result means that
although the testing laboratory detected a DNA alter-
ation, there was not enough evidence to classify that al-
teration as deleterious or neutral. In the case of BRCA, a
VUS result gives no clear indication as to whether or
not the patient is at higher risk for developing breast or
ovarian or another cancer, and further studies are neces-
sary to determine the significance (or not) of the variant
in question.
International collaborative studies of the clinical mean-
ing and significance of VUS results in the context of
BRCA1/2 testing, as well as the ethical and policy implica-
tions, have been ongoing since the 1990s [1,12-15]. These
include efforts by the Breast Cancer Information Core
(BIC) Working Group (part of the US National Human
Genome Research Institute (NHGRI)) and the Inter-
national Agency for Research on Cancer (IARC) Unclassi-
fied Genetic Variants Working Group (part of the World
Health Organization)[16-18].
In the United States, Myriad Genetics was the only com-
mercial testing laboratory for BRCA1/2 until the June
2013 Supreme Court ruling that overturned the patent-
ability of genomic DNA [19]. This enabled Myriad to col-
lect the largest single proprietary database of BRCA1/2
testing results, and one consequence was a low VUS rate:
in 2013, Myriad reported a VUS rate of 2.1% [2]. Immedi-
ately after the Supreme Court ruling, several laboratories
began offering BRCA testing or announced that they
would do so. VUS rates for BRCA1/2 tests and VUSreclassification procedures vary among the different gene
testing laboratories now offering testing (Additional file 1)
[20]. For instance, Ambry Genetics reports a VUS
rate of 3.64% [21], while some European laboratories
have reported a 15% VUS rate for BRCA1/2 [22].
Certain for-profit companies, such as Myriad, con-
sider the databases, algorithms and processes through
which variant classification occurs to be proprietary
information. As a result, specific details are often not
released, and VUS rates cannot be independently
verified. However, several general strategies for classi-
fying variants and making informed predictions about
disease risk are known [2,14,15,22,23]. International
academic collaborations of clinicians and scientists,
such as the ENIGMA consortium, are working to define
a rigorous and consistent approach for variant classifi-
cation [15].
Various lessons can be gleaned from the BRCA1/2 ex-
perience, especially with regard to Myriad Genetics. Over
time, Myriad’s large centralized database enabled variants
to be initially classified as VUS and then efficiently reclas-
sified as being more likely to be deleterious or neutral - a
testament to the utility of a large, well-curated, centralized
database [2]. However, the proprietary nature of Myriad’s
database meant that it was inaccessible to many re-
searchers and clinicians, and testing by other laboratories
who lack access to the database continues to produce
higher VUS rates - a testament to the importance of
data sharing and collation by all testing providers, and
an example of the challenges created by proprietary
databases [24].
The classification and reporting of genetic testing re-
sults vary internationally (Table 1). The IARC Working
Group suggests a five category system for reporting se-
quence variations: pathogenic, likely pathogenic, uncer-
tain, likely neutral, and neutral [18]. Similarly, the Dutch
and British societies for clinical molecular genetics sug-
gest reporting sequence variants in five classes: (1)
clearly not pathogenic; (2) unlikely to be pathogenic; (3)
unknown significance (VUS); (4) likely to be pathogenic;
and (5) clearly pathogenic [25]. The American College of
Medical Genetics (ACMG) proposes six categories: (1)
previously reported and causative of the disorder; (2) not
previously reported but expected to cause the disorder;
(3) not previously reported and may or may not cause
the disorder; (4) not previously reported but probably
does not cause the disorder; (5) previously reported and
known to be neutral; and (6) not expected to cause
the disorder but reported to be associated with a clinical
presentation [26]. The ACMG category (1) and the IARC
‘pathogenic’ classification both refer to a deleterious muta-
tion, a genetic variation or sequence alteration that causes
an elevated risk of disease. A negative or neutral test result
does not necessarily indicate that there is no increased
Table 1 Examples of recommendations for genetic variant classification
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Genetic Laboratory
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aCategories have been summarized for brevity. VUS, variants of uncertain significance.
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tory. Rather, it indicates that elevated risk cannot be attrib-
uted to known mutations in BRCA1/2 genes. However, a
negative test result can still be informative when a patient
has tested negative for a particular deleterious mutation
already known to run in his/her family. The ACMG cat-
egory (3) and the IARC ‘uncertain’ classification both indi-
cate a VUS result, meaning that while the analysis
detected a variation in the sequence, the causal relation-
ship between this particular variation and hereditary risk
of disease is unclear (Table 1).
A true VUS, with insufficient evidence to clearly indi-
cate pathogenicity or neutrality, is treated as clinically
uninformative. In this case, other information, such asfamily history, is used to make clinical management de-
cisions [11,27,28]. In practice, ACMG categories (2) and
(3) are sometimes combined or managed similarly be-
cause neither is considered to be a clinically actionable
result. However, there has been some controversy over
the clinical management of a result that is ‘likely patho-
genic’ or ‘expected to cause the disorder’ and whether
such results should essentially be treated as a VUS or as
a deleterious result [14,18,26,29].
Methods of VUS reclassification
VUS results can subsequently be reclassified as likely dele-
terious or likely neutral as more information becomes avail-
able. Reclassification procedures and methods vary among
Cheon et al. Genome Medicine 2014, 6:121 Page 4 of 10
http://genomemedicine.com/content/6/12/121laboratories and can include the following: assembling evi-
dence from additional testing of relatives, discovery of the
same variants in other families, biological methods such as
RNA transcript analysis, creating knock-in or knock-out
animal models, or performing gene rescue studies. Another
method is finding variants in tandem with known dele-
terious mutations, because two deleterious mutations
are generally incompatible with surviving past embry-
onic development [30]. Genetic, epidemiological and
histopathological features, and animal model, in vitro
(tissue culture) and in silico (bioinformatic) analyses
may all be used to reclassify variants [31]. Finding vari-
ants in large numbers of people who are unaffected, as
reflected in a high allele frequency in population studies,
for example, is a powerful method for reclassifying vari-
ants as unlikely to be deleterious [32]. However, the large
number of individuals required for such studies will be a
challenge when studying variants that are very rare in the
population [31]. Various probability and multi-factorial
models have also been proposed for the reclassification of
variants [1,14,22,33]. These and other considerations help
classify an initial VUS as likely to be a deleterious muta-
tion or likely to be a neutral polymorphism.
Guidelines for the classification of genetic variants have
been proposed for both research and clinical purposes. Al-
though there is no consensus regarding procedures for the
reclassification of VUS, the main guidelines used in the
United States are the recommendations and updates from
the ACMG [26,34], while analogous European guidelines
have been proposed by the European Society of Human
Genetics [35]. In 2008, the ACMG issued a revision of the
2007 standards for reporting sequence variations, which
specified interpretive categories for sequence variations to
be used in clinical reports [26]. Categorization is based on
several factors, such as whether the variation causes a non-
sense, missense or frameshift mutation in the genetic cod-
ing sequence. Other factors are the location of the variation
in the exon or intron sequence and the possibility that
the change in sequence could produce a new splice site or
eliminate a known splice site. However, large-scale chromo-
somal rearrangements, such as inversions, deletions and in-
sertions, may be missed by some methods, and their effect
on gene function can be difficult to predict.
The logic of testing multiple genes despite high
rates of VUS
Two decades of BRCA testing and research have pro-
duced BRCA VUS rates that are lower than for most
other genes. The move to testing many genes in a ‘panel’
(also known as multi-gene or multiplex testing), or per-
forming WGS/WES, increases the likelihood that a VUS
will be detected in at least one gene because far more
genes are being tested, and variants uncovered in other
genes are more likely never to have been seen [3,4,36].Many laboratories, both commercial (such as Myriad
Genetics, Ambry Genetics, GeneDx, Invitae, Quest, LabCorp,
Counsyl and others [37-43]) and academic (such as those
affiliated with the University of Washington, University of
California Los Angeles, University of Chicago, Emory
University and others [44-47]), are now offering multi-
gene testing, WES and/or WGS. For some examples of
BRCA-related multi-gene testing, see Additional file 1.
These tests allow for simultaneous analysis of multiple
genes (multiplex testing) or the entire genome at a cost
that is often only slightly greater than a single gene test
[20,48]. These tests may involve sequencing various
numbers of genes, from 2 to over 100 or 200 genes, the
entire exome (selecting for protein-coding sequences)
or the entire genome [48]. Panels and WGS analyses are
being used as predictive and diagnostic tests in oncol-
ogy, cardiology and other clinical contexts.
Multi-gene testing can lead to additional findings of clin-
ically relevant information. There have been cases in which
multi-gene panels detected pathogenic mutations that
would not have been identified if BRCA1/2 testing alone
had been used, leading to a change in care and the early de-
tection of cancers [4]. The use of WGS and WES seems
particularly promising in the treatment of patients who
have been on diagnostic odysseys and are suspected to suf-
fer from rare Mendelian (single-gene) conditions [49].
While WGS and multi-gene panels have the potential to in-
crease clinically relevant findings, such testing substantially
increases the volume of detected variants per individual,
and the interpretation of these requires significant clinical
and laboratory labor [3,36,50].
Despite the difficulties, the logic of testing multiple genes
remains compelling. Cancer is a complex genetic disease.
Breast and ovarian cancers, for example, are associated with
many genes, not just BRCA1/2 [11]. Other cancers, apart
from breast and ovarian cancer, are also associated with
BRCA1/2 mutations [51,52]. The pleiotropy of cancer-
associated mutations raises questions about penetrance,
gene interactions and other factors, all of which compli-
cate clinical interpretation. With the power of sequence
analysis increasing and the cost plummeting, multi-
gene panels, WES and WGS are now used in both re-
search and clinical care [49,53,54]. This is especially
prevalent in fields already using genomics in the clinical
setting, particularly in the treatment of cancer, cardiac
disease and diabetes. With sequencing costs continuing
to drop, current tests that examine single genes or just a
few genes may eventually be replaced by panels, WES,
WGS, or other methods that provide far more informa-
tion for similar or lesser cost.
We are not advocating for immediate and indiscrimin-
ate multi-gene testing without regard to patient history
and other relevant context. However, gene panels are
already on the market, and it is necessary to consider
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sequencing capacity has outpaced interpretive ability.
Ethical issues and policy implications
VUS results raise numerous ethical and policy issues
(Table 2). In particular, the uncertainty raised by VUS
results may lead to misunderstanding by patients and
professionals, while the issue of where responsibility lies
regarding the duty to re-contact patients if new infor-
mation arises remains unresolved. In the context of
BRCA1/2 testing, it is unclear how patients understand
and deal with the uncertainty raised by a VUS result
[55,56]. Do they understand what VUS results do - or
do not - mean? How do different patients react? Some
reports suggest that patients may misinterpret a VUS re-
sult as non-deleterious, while clinicians may misinterpret
them as deleterious and make potentially inappropriate
management suggestions [57]. Furthermore, what do clini-
cians and genetic counselors do to follow up VUS results?
Do they apply bioinformatic interpretation tools? Do they
submit variants for further analysis using biological
methods or in animal models? Do they notify membersTable 2 Major policy issues
ELSI challenges Policy questions
Duty to re-contact To what extent healthcare providers have a duty
re-contact patients in the case of a reclassified V
Informed consent Considerations and options within the informed
consent process
Patient understanding How to reduce uncertainty introduced by VUS r
that can lead to misunderstanding by patients
and professionals
Data sharing How to aggregate data on VUS from disparate c
and research laboratories, particularly those perf
gene panel or WES/WGS analyses
Research to improve
VUS interpretation
How to improve the evidence base for interpret
of genomic variants
EHR, electronic health record; ELSI, ethical, legal and social implication; VUS, variant
whole-genome sequencing.of the ENIGMA consortium [15]? What do healthcare pro-
viders discuss with their current patients and how could we
help them to better serve patients? Policies to encourage
data sharing and curation can help to speed up the rate of
VUS interpretation, and avoid some of the pitfalls of propri-
etary databases, as exemplified by the Myriad experience.
Duty to re-contact
A lack of consensus about when and whether a phys-
ician, researcher or genetic counselor has a duty to re-
contact patients upon variant reclassification adds an
additional layer of ethical and logistical complexity to
the technical uncertainty [58]. When new information
that sheds light on the clinical significance of a variant is
discovered, is it the responsibility of the laboratory, the
clinician or the genetic counselor to contact the person
who carries the mutation? Or is it the responsibility of
the affected person to periodically check back? Where
does responsibility lie, and what degree of evidence trig-
gers a need to share newfound information?
The problem of re-contacting patients is far from simple.
At the least, genetic testing generally involves a clinician, aPossible solutions
to
US
• EHRs and integration of genomic data into EHRs
• Rely on patient to request new interpretation
• Patient access to databases
• Formulate standard practices for re-contact
• Integrate notification of users (health professionals,
counselors or consumers) into databases, websites
and interpretive software
• Broad consent
• Opt out option for some results
• Options for re-contact integrated into consent process
esults • Careful pretest counseling with qualified genetic
counselors or other health professionals
• Education of clinicians, counselors and consumers
• Resources to assist consumers in interpreting test results
linical
orming
• Centralized open-access database
• Make deposition of data and methods sufficient to enable
independent verification a condition of payment
• Accreditation of laboratories contingent on independent
verification and data sharing
• Condition of certification for laboratory directors and/or
genetics health professionals
ation • Public and private research programs
• Individual research projects
• Consortia and formal research networks
• Studies of ethical, legal and practical experience in using
gene panels and WGS/WES analysis
s of uncertain significance; WES, whole-exome sequencing; WGS,
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one of these may change address or may no longer be
performing the same duties when a VUS interpretation
changes. Where should responsibility lie for relaying in-
formation about reclassification - with the patient, the
laboratory, the genetic counselor, the clinician or some
combination?
Currently, some laboratories report VUS reclassifica-
tions to the healthcare provider or genetic counselor
who ordered the test. It is then that health professional’s
responsibility to get back in touch with the patient. A
problem with this system arises when healthcare providers
have out of date patient contact information, resulting in
an inability to re-contact the patient or family. Wasted
time and resources at the stage of re-contacting the pa-
tient will become more significant as multi-gene panels
produce high rates of VUS and subsequent reclassification.
Some groups may not have the manpower or resources
needed to follow up reclassified VUS results for all tested
patients. In addition, not all laboratories have systems in
place for ensuring that reclassified variants are regularly
reported back to the healthcare professional who ordered
the test (Additional file 1) [20]. Current practices are in-
corporating the capacity to relay new information about
variant calls as it becomes available, but the process is not
uniform or universal.
Additional pragmatic issues arise when a physician or
genetic counselor leaves a particular practice, or if a
practice closes entirely, making re-contact with the asso-
ciated patients difficult, if not impossible. Electronic
health records (EHRs) have the potential to help, in that
medical records, including test results, would be elec-
tronically available across sites of care. However, inter-
operability and compatibility across different platforms
remain substantial hurdles for EHR systems, so that re-
sults from tests ordered at one site may not be trans-
ferred to an alternative EHR system. Because some
genetic testing is also done via smaller individual clinics
which may use different, or not have any, EHR systems,
as opposed to comparatively larger healthcare organiza-
tions, these issues could significantly contribute to long-
term inconsistencies in handling patient medical records
and maintaining patient contact. The practices and infra-
structure to enable reclassification are under construction,
as are those necessary for conveying reclassification infor-
mation to patients getting testing and the professionals
who provide their health care.
In the context of multi-gene panels and WES/WGS,
issues regarding the scale and complexity of VUS reclas-
sification are compounded and magnified [36]. This is
because the other genes on these panels are far less
studied than BRCA1/2 and, upon testing, are much
more likely to produce VUS results. While some may
argue that this is a reason not to do gene panels untilfurther research is completed, the fact remains that
multi-gene panels are already being introduced into clin-
ical use by many laboratories, and they are being
demanded by healthcare providers and patients alike
[48,59]. Indeed, the management of VUS results will be
one of the core features of a multi-institutional Pro-
spective Registry of Multiplex Testing (PROMPT) study
at the Mayo Clinic, Memorial Sloan Kettering Cancer
Center, and the University of Pennsylvania [60].
Data-sharing and curation of databases
Commercial, academic and non-profit laboratories are
using the availability of additional genes in a single panel
as a marketing tool - a ‘more is better’ approach. In the
United States, the rapid uptake of multi-gene tests may
be partly attributable to the highly commercialized na-
ture of medicine and health care, increasing the likeli-
hood of competitive pressure resulting in tests being
introduced into clinical care before there is a well-
established evidence base for optimal use [53,61-63].
While the VUS rate should drop over time, the prospect
of dealing with many VUS results will confront the sys-
tem immediately and for the foreseeable future [3,4,36].
Healthcare providers and patients will continue to face
uncertainty while making life-changing decisions about
treatment. With current and future patients in mind,
how can we lower the VUS rates as fast as possible?
The key to improving the interpretation of VUS results,
and thus lowering the overall VUS rate, is the accumula-
tion and organization of high-quality data and the devel-
opment of robust methods for data interpretation. The
data will come as a result of testing large numbers of pa-
tients and following up on their clinical outcomes. In the
case of BRCA1/2, Myriad’s previous patent position led to
the company performing the vast majority of testing in the
United States. This allowed Myriad to accumulate and col-
late genomic, pedigree and clinical data, enabling them to
maintain the lowest VUS rate achieved so far. Myriad con-
tributed to the BIC database until 2006 (with their last
large data contribution in November 2004), but thereafter
maintained a proprietary database, largely inaccessible to
academic researchers, non-profit organizations and the
patients who had sent their samples for analysis.
The situation for multi-gene panels and WES/WGS
will be different because there are many genetic testing
companies on the market already offering their own
gene panels or sequencing services. Competition among
companies has led to more competitive pricing, but also
to multiple places in which data are held, some of which
may remain proprietary and therefore not widely access-
ible. We suggest that the fastest way to accumulate data
and lower VUS rates is to ensure that all of the data
eventually go to one accessible place. How can we en-
courage this outcome in a competitive marketplace?
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creation of a centralized database for gene variants. This
does not imply that all data of all kinds should be in a
single database; rather, we suggest the creation of a data-
base designed for clinical use containing the core data
used by those interpreting genomic variants. Reclassifi-
cation of variants happens using a variety and combin-
ation of methods, including functional assays, pedigree/
family histories and statistical analyses. The importance
of a centralized database is in the convergence of these
many pieces of data for a meaningful and accurate re-
classification of VUS, although even a large centralized
database does not eliminate the need for additional clin-
ical interpretation, statistical analyses and further re-
search. The ClinVar database, an open-access National
Center for Biotechnology Information (NCBI)-funded
resource connecting genome variations and phenotypes,
has the potential to fulfill this role [64], in a similar
manner to the BIC and others [31], but with a clinical
focus that also includes a greater range of genetic disor-
ders. However, its construction faces a number of ethical,
commercial, legal and logistical obstacles. Some of the
legal and ethical issues concern the maintenance of patient
privacy and ensuring informed consent. ClinVar and the
laboratories and research institutions collaborating with
and contributing to it are working to address these issues.
From an intellectual property perspective, why would en-
tities with monetary or commercial interests be willing to
share proprietary information? The main logistical issues
concern the lack of existing infrastructure for data sharing,
the development of interpretive algorithms, and obtaining
funding to maintain the database.
There are currently many groups working to address
some of these data-sharing issues, particularly by creat-
ing repositories in which data can be collated [15,64-69].
Such efforts have not yet converged on a single centralized
database, although as previously mentioned, ClinVar may
emerge as the main hub for clinical interpretation. These
efforts have also been hindered because not all databases
are up to date and reliable, and some locus-specific data-
bases are small operations [31,70]. This is unsurprising
given that many of the databases were established to en-
able research, and funding is unstable or insufficient to
support use as a reliable clinical tool. Policies that create
incentives for participation in public databases are the
most promising way to expedite clinical interpretation of
genomic data in the long run.
Competition in the genetic testing market means that in-
surance companies, health plans and other payers (govern-
ment or otherwise) have a strong influence. The degree of
competition in genetic testing depends on how a healthcare
system is organized. BRCA testing in the United Kingdom,
for example, remained largely under the auspices of the
National Health Service, despite Myriad’s UK patent rights[71]. In Canada, Myriad’s effort to enforce its patents
through its licensee was resisted by the Health Ministry
(and ultimately the Premier) of the Province of Ontario,
which refused to force its provincial health system to stop
BRCA testing. Myriad never sued, so in effect Myriad’s pat-
ents in Canada have not been enforced [72]. Children’s
Hospital of Eastern Ontario recently filed a lawsuit contest-
ing patents on genes associated with long QT syndrome
[73]. One purpose of the litigation is to clarify Canadian
law on whether genes can be patented. And in Australia, la-
boratories under the provincial health systems continue to
offer BRCA testing under a voluntary agreement by the
BRCA-testing licensee [74]. A recent review of the effects
of patents on genetic testing in Australia paints a nuanced
picture and cautions ‘against extrapolating [views on effects
of patents on genetic testing] survey results from one juris-
diction to another’ [75]. The role of patents thus differs
among jurisdictions, but the central importance of pooling
data and sharing methods is global.
Policy change could encourage the sharing of data
needed to make and verify clinical interpretations of gen-
etic variants. For instance, a requirement for reimburse-
ment could be that laboratories offering tests must share
sufficient information about methods and sufficient data
for independent verification of results and interpretation.
Such a policy could be an effective method of encouraging
laboratories to contribute to public databases and to share
their interpretive algorithms. Another policy option is to
pay directly for interpretive services, but only on condition
of sufficient disclosure to enable independent verification.
These policy changes could be implemented either as cri-
teria for accreditation (such as those set by the Inter-
national Organization for Standardization (ISO) in much
of Europe; Clinical Pathology Accreditation (CPA) in the
United Kingdom, although CPA accreditation is currently
being transitioned over to ISO; laboratory accreditation
under the College of American Pathologists), certification
of health professionals (such as those set by the Clinical
Laboratory Improvement Amendments in the United
States), or as a condition of laboratory reimbursement
stipulated by insurers and health plans that pay for the
tests [12,16,76,77].
How and when to re-contact patients if new information
emerges could also become more consistent as a matter of
policy. One option is the effective implementation of
EHRs, in which a patient could directly update contact in-
formation on a single record that stays with him or her, re-
gardless of the specific healthcare provider. This would,
however, also require the integration of clinically relevant
genomic data into the EHR, which remains a challenge.
Even with the infusion of public funding, the implementa-
tion of a well-functioning, reliable EHR system requires
significant additional investment, and wide-scale imple-
mentation has proved to be difficult [62,78-80]. Informed
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tient’s responsibility to periodically check back in with
their provider after a VUS result would put the onus on
patients, and avoid some of the pitfalls of patients chan-
ging address or changing physicians. Another option is to
design a database that manages genotypes and pheno-
types so that interested patients can search for updates
themselves. In the event of a reclassification, they could
re-contact their healthcare providers to discuss further
options. Direct consumer use of genotype databases
would, however, present a daunting technical challenge
because users would require a simplified interface de-
signed for infrequent and non-expert users, not just for
genetic professionals. The Patient-Centered Outcomes
Research Institute (PCORI) has announced plans to
spend US$100 million building PCORnet to empower
individuals and families to participate in research. Several
genetic organizations have joined early efforts to harness
this power, including PCORnet, the Genetic Alliance,
Facing Our Risk of Cancer Empowered and Duchenne-
Connect [81-84]. These efforts will help pave the way to
stronger patient engagement, and will provide lessons on
how best to manage patient re-contact, informed consent
and access to clinical data and databases.
Another important policy to improve the clinical inter-
pretation of genomic variation is arguably the most im-
portant of all: continuing support for research efforts
that have been sustained for three decades on develop-
ing methods for functional biological analysis, fostering
bioinformatic methods, and detecting such variants.
These efforts are global, and include networks in Europe,
North America and Asia, and increasing attention to
‘translational’ research efforts, in moving from genomic
discovery to clinical utility.
Conclusions
In this article, we use some lessons learned from BRCA1/2
testing to anticipate challenges that will emerge from the
rise in VUS results due to the increasing use of multi-gene
panels and WES/WGS. Experience with BRCA1/2 is help-
ful, but not fully generalizable. The BRCA1/2 genes are
large and mutations in them are spread widely, and the
unusual - perhaps unique - US service monopoly that gave
rise to a proprietary database might not presage experi-
ence with other genes. But the central point is that stan-
dards for informed consent, how and when to inform
those who have VUS that their variants have been reclassi-
fied, and the infrastructure for storing and interpreting
genomic variants are truly important, and policies are
required to build the requisite infrastructure and de-
velop the data-sharing and curation practices that will
be needed.
While international efforts to classify and reclassify
variants are ongoing, the system for reclassifying andhandling VUS results in clinical care is evolving rapidly.
It is not entirely consistent and some elements, such as
data-sharing practices, are fragile and incomplete. Al-
though there will be higher rates of VUS as more un-
familiar genes are tested as part of panels, the logic for
testing many genes in an effort to understand complex
diseases remains compelling. Ethical, legal and policy
implications center on data sharing, curation, patient re-
contact and incentives for contributing data to public
databases. We argue that an open-access centralized
database is a necessary element, although it will not it-
self be sufficient, in efforts to reclassify VUS in the
shortest amount of time possible.
Beyond infrastructure, there is a pressing need for fur-
ther research on the social, ethical and legal implications
of VUS results for patients and healthcare providers who
are already dealing with VUS, multiplex panels and
WES/WGS on the ground. Such work is underway in
many of the large-scale clinical sequencing grant pro-
grams in North America and Europe. Uncertainty will
persist until many genes in many people have been ana-
lyzed and longitudinal studies have been completed on
their long-term health outcomes.
Ensuring the rapid and effective sharing of data and
methods will require investment to build the necessary
infrastructure for rapid VUS reclassification, and lower-
ing of VUS rates will take time and resources. However,
there is an urgent need for government, healthcare pro-
viders and researchers to invest time and effort immedi-
ately because managing VUS results is already having a
direct impact on patient management and care, and as
more genes are analyzed, the issues will only intensify.
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